Professor of Infectious Diseases in Global Health, The University of Manchester
Dr Denning is an infectious diseases clinician with expertise in fungal diseases. He graduated from Guys Hospital in 1980 and trained in general medicine, paediatrics, microbiology and infectious diseases in London, Glasgow and Stanford, California. He was appointed as a Senior Lecturer and honorary Consultant in Infectious Diseases in Manchester in 1990, and promoted to Professor in 2005. Dr Denning was the Founding Director of the National Aspergillosis Centre, Manchester, a referral centre in the UK for all patients with chronic pulmonary aspergillosis (2009-2020). His current academic interests are chronic and allergic pulmonary fungal disease, the global burden of fungal infection, resistance in Aspergillus and getting new antifungals developed. He has published extensively (>600 academic papers) and has a citation H-index of 121. He serves as the Chief Executive of the Global Action Fund for Fungal infections (GAFFI) and Professor of Infectious Diseases and Global Health at the University of Manchester, UK. He leads LIFE (Leading International Fungal Education (www.LIFE-Worldwide.org), which is focused on improving patient outcomes through online education. GAFFI advocates for access to fungal diagnostics and antifungal therapies. He is the founder of 2 biotechnology companies – F2G Ltd (antifungal drug discovery and development in phase 2) and Myconostica Ltd (now Novacyt) for molecular diagnostic tests for fungi.